Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: A pathogenic marker

Annals of Neurology

Volumn 59, Issue 3, 2006, Pages 520-526

  Banno, Haruhiko ^a   Adachi, Hiroaki ^a   Katsuno, Masahisa ^a   Suzuki, Keisuke ^a   Atsuta, Naoki ^a   Watanabe, Hirohisa ^a   Tanaka, Fumiaki ^a   Doyu, Manabu ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; LEUPRORELIN; MUTANT PROTEIN; POLYGLUTAMINE;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; DISEASE SEVERITY; DRUG MECHANISM; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KENNEDY DISEASE; MALE; MOTOR NEURON DISEASE; NUCLEOTIDE REPEAT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SCROTUM; SKIN EPITHELIUM; SPINAL CORD;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CELL COUNT; CREATINE KINASE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUPROLIDE; MALE; MIDDLE AGED; MUSCULAR ATROPHY, SPINAL; MUTATION; PEPTIDES; RECEPTORS, ANDROGEN; SCROTUM; SKIN; SPINAL CORD; STATISTICS; TIME FACTORS;

EID: 33644823759     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20735     Document Type: Article

References (30)

1. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology 1968;18:671-680.
2. Sperfeld AD, Karitzky J, Brummer D, et al. X-linked bulbospinal neuropathy: Kennedy disease. Arch Neurol 2002;59:1921-1926.
3. Sobue G, Hashizume Y, Mukai E, et al. X-linked recessive bulbospinal neuronopathy: a clinicopathological study. Brain 1989;112:209-232.
4. Katsuno M, Adachi H, Tanaka F, et al. Spinal and bulbar muscular atrophy (SBMA): ligand-dependent pathogenesis and therapeutic perspective. J Mol Med 2004;82:298-307.
5. Sobue G, Adachi H, Katsuno M. Spinal and bulbar muscular atrophy (SBMA). In: Dickinson D, ed. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: INS Neuropathology, 2003:275-279.
6. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-79.
7. Tanaka F, Doyu M, Ito Y, et al. Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum Mol Genet 1996;5:1253-1257.
8. Doyu M, Sobue G, Mukai E, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992;32:707-710.
9. Shimada N, Sobue G, Doyu M, et al. X-linked recessive bulbospinal neuronopathy: clinical phenotypes and CAG repeat size in androgen receptor gene. Muscle Nerve 1995;18:1378-1384.
10. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000;23:217-247.
11. Li M, Miwa S, Kobayashi Y, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 1998;44:249-254.
12. Li M, Nakagomi Y, Kobayashi Y, et al. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 1998;153:695-701.
13. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805-810.
14. Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002;35:843-854.
15. Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003;9:768-773.
16. Adachi H, Katsuno M, Minamiyama M, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005;128:659-670.
17. Sobue G, Doyu M, Kachi T, et al. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 1993;117:74-78.
18. Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002;59:770-772.
19. Takeyama K, Ito S, Yamamoto A, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002;35:855-864.
20. Chevalier-Larsen ES, O'Brien CJ, Wang H, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 2004;24:4778-4786.
21. Shimohata T, Kimura T, Nishizawa M, et al. Five year follow up of a patient with spinal and bulbar muscular atrophy treated with leuprorelin. J Neurol Neurosurg Psychiatry 2004;75:1206-1207.
22. Norris FH Jr, Calanchini PR, Fallat RJ, et al. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974;24:721-728.
23. Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995;378:403-406.
24. Terao S, Sobue G, Hashizume Y, et al. Age-related changes in human spinal ventral horn cells with special reference to the loss of small neurons in the intermediate zone: a quantitative analysis. Acta Neuropathol (Berl) 1996;92:109-114.
25. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993.
26. Hayashi Y, Kakita A, Yamada M, et al. Hereditary dentatorubral- pallidoluysian atrophy: ubiquitinated filamentous inclusions in the cerebellar dentate nucleus neurons. Acta Neuropathol (Berl) 1998;95:479-482.
27. Paulson HL, Perez MK, Trottier Y, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997;19:333-344.
28. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
29. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
30. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999;282:790-795.